Forcing dividing cancer cells to die; low-dose drug combinations to prevent spindle pole clustering

被引:4
|
作者
Ducrey, Eloise [1 ,2 ,3 ]
Castrogiovanni, Cedric [3 ,4 ]
Meraldi, Patrick [3 ,4 ]
Nowak-Sliwinska, Patrycja [1 ,2 ,3 ]
机构
[1] Univ Geneva, Sch Pharmaceut Sci, Fac Sci, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
[2] Univ Geneva, Inst Pharmaceut Sci Western Switzerland, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
[3] Translat Res Ctr Oncohaematol, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
[4] Univ Geneva, Dept Cell Physiol & Metab, Sch Med, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
基金
瑞士国家科学基金会;
关键词
Mitosis; Drug combination; Cancer; Centrosome clustering;
D O I
10.1007/s10495-021-01671-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mitosis, under the control of the microtubule-based mitotic spindle, is an attractive target for anti-cancer treatments, as cancer cells undergo frequent and uncontrolled cell divisions. Microtubule targeting agents that disrupt mitosis or single molecule inhibitors of mitotic kinases or microtubule motors kill cancer cells with a high efficacy. These treatments have, nevertheless, severe disadvantages: they also target frequently dividing healthy tissues, such as the haematopoietic system, and they often lose their efficacy due to primary or acquired resistance mechanisms. An alternative target that has emerged in dividing cancer cells is their ability to "cluster" the poles of the mitotic spindle into a bipolar configuration. This mechanism is necessary for the specific survival of cancer cells that tend to form multipolar spindles due to the frequent presence of abnormal centrosome numbers or other spindle defects. Here we discuss the recent development of combinatorial treatments targeting spindle pole clustering that specifically target cancer cells bearing aberrant centrosome numbers and that have the potential to avoid resistance mechanism due their combinatorial nature.
引用
收藏
页码:248 / 252
页数:5
相关论文
共 50 条
  • [21] Low-dose carbon monoxide suppresses metastatic progression of disseminated cancer cells
    Zhang, Tiantian
    Zhang, George
    Chen, Xiang
    Chen, Zhengming
    Lin, Anthony
    Zhang, Cheryl
    Torres, Lisa K.
    Bajrami, Sandi
    Zhang, Tuo
    Zhang, Guoan
    Xiang, Jenny Z.
    Hissong, Erika M.
    Chen, Yao-Tseng
    Li, Yi
    Du, Yi-Chieh Nancy
    CANCER LETTERS, 2022, 546
  • [22] Environmental oestrogens and breast cancer: long-term low-dose effects of mixtures of various chemical combinations
    Darbre, Philippa D.
    Fernandez, Mariana F.
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2013, 67 (03) : 203 - 205
  • [23] Adaptive response analysis of colorectal cancer cells to low-dose oxaliplatin as a tool to deciphering mechanisms of synergistic drug interaction.
    Tosi, Diego
    Robin, Mathilde
    Bini, Marta
    Marchive, Candice
    Djiane, Alexandre
    Heron-Milhavet, Lisa
    Brehelin, Laurent
    Gongora, Celine
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects
    Loetsch, Jorn
    Geisslinger, Gerd
    DRUG DISCOVERY TODAY, 2011, 16 (23-24) : 1001 - 1006
  • [25] Evidence of low-dose hyper-radiosensitivity in normal cells of cervix cancer patients?
    Slonina, D.
    Biesaga, B.
    Urbanski, K.
    Kojs, Z.
    Waligorski, M.
    RADIATION PROTECTION DOSIMETRY, 2006, 122 (1-4) : 282 - 284
  • [26] Determination of the adequate dosage of rebamipide, a gastric mucoprotective drug, to prevent low-dose aspirin-induced gastrointestinal mucosal injury
    Ota, Kazuhiro
    Takeuchi, Toshihisa
    Nouda, Sadaharu
    Ozaki, Haruhiko
    Kawaguchi, Shinpei
    Takahashi, Yoshiaki
    Harada, Satoshi
    Edogawa, Shoko
    Kojima, Yuichi
    Kuramoto, Takanori
    Higuchi, Kazuhide
    JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2016, 59 (03) : 231 - 237
  • [27] THE TREATMENT OF ADVANCED HODGKINS-DISEASE WITH ALTERNATING POTENTIALLY NON-CROSS-RESISTANT DRUG-COMBINATIONS AND LOW-DOSE RADIOTHERAPY
    STRAUS, DJ
    MYERS, J
    NISCE, L
    LEE, BJ
    KOZINER, B
    MCCORMICK, B
    YOUNG, CW
    CLARKSON, BD
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1983, 2 (03) : 339 - 346
  • [28] Synergistic radiosensitization of lung cancer cells using parthenolide and low dose combinations of proteasome or cycloxygenase inhibitors
    Warren, GW
    Grimes, K
    Crooks, PA
    St Clair, WH
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S391 - S392
  • [29] Daily low-dose aspirin in cancer patients with central venous catheter: new role for an old drug
    Giuseppe Curigliano
    Alessandra Balduzzi
    Aron Goldhirsch
    Marco Colleoni
    Supportive Care in Cancer, 2008, 16 : 313 - 314
  • [30] Low-Dose Rivaroxaban to Prevent Recurrences of Venous Thromboembolism in Cancer: A Real-Life Experience with a Focus on Female Patients
    Santini, Paolo
    Mosoni, Carolina
    D'Errico, Alessandro
    Porceddu, Enrica
    Lupascu, Andrea
    Valeriani, Emanuele
    Tondi, Paolo
    Pola, Roberto
    Porfidia, Angelo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)